For those denying the effectiveness of early treatment, this is your legacy:
unnecessary deaths
Based on adoption and early outpatient use of the current best treatment when it was known to be effective from multiple studies at p = 0.01 (ivermectin from Oct 9, 2020, and HCQ from May 19, 2020), and adjusting for the estimated fraction of the world that adopted these treatments. The total number of COVID-19 deaths is
There have been 76 controlled studies of ivermectin for COVID-19, authored by 718 scientists, with 57,623 patients. Meta analysis shows a 66% improvement for early treatment, relative risk 0.34 [0.25-0.47].
There have been 306 controlled studies of HCQ for COVID-19, authored by 4,906 scientists, with 423,754 patients. Meta analysis shows a 64% improvement for early treatment, relative risk 0.36 [0.29-0.46] (HCQ is not effective when used too late).
Many other early treatments are effective, for example vitamin D and bamlanivimab (LY-CoV555). Using multiple treatments, especially with different mechanisms of action, is likely to further reduce deaths.
Chowdhuryhosp., p=0.23 Espitia-Hernandezrecov. time, p<0.0001 Carvallodeath, p=0.08 Mahmuddeath, p=0.25 Szente Fonsecahosp., p=0.53 Cadegianideath, p=0.50 Ahmedsymptoms, p=0.09 Chaccoursymptoms, p<0.05 Ghaurino recov., p=0.04 Babalolaviral+, p=0.11 Ravikirtideath, p=0.12 Bukhariviral+, p<0.0001 Mohanno recov., p=0.27 Biberhosp., p=0.34 Elalfyviral+, p<0.0001 López-Medinadeath, p=0.50 Royrecov. time, p=0.87 Chahlano disch., p=0.004 Mouryaviral+, p<0.0001 Louedeath, p=0.34 Merinohosp., p<0.001 Faisalno recov., p=0.005 Arefrecov. time, p=0.0001 Krolewieckiventilation, p=1.00 Vallejosdeath, p=0.70 Together Trialdeath, p=0.54 Buonfratehosp., p=0.47 Mayerdeath, p<0.0001 Borodydeath, p=0.03 Abbasdeath, p=1.00 Ivermectin early treatment Shoumansymp. case, p<0.001 Carvallocases, p<0.0001 Beheracases, p=0.0007 Carvallocases, p<0.0001 Hellwigcases, p<0.02 Bernigauddeath, p=0.08 Alamcases, p<0.0001 IVERCOR PREPcases, p<0.0001 Chahlam/s case, p=0.002 Beheracases, p<0.001 Taniokadeath, p=0.002 Seetsymp. case, p=0.0009 Morgensternhosp., p=0.50 Mondalsymp. case, p=0.006 Samajdarcases, p<0.0001 Kerrdeath, p<0.0001 Ivermectin prophylaxis Favorsivermectin Favorscontrol
Gautretviral+, p=0.001 Huangno recov., p=0.02 Esperhosp., p=0.02 Ashrafdeath, p=0.15 Huangviral- time, p<0.0001 Guérindeath, p=1.00 Chenviral- time, p=0.01 Derwanddeath, p=0.12 Mitjàhosp., p=0.64 Skipperdeath/hosp., p=0.58 Hongviral+, p=0.001 Bernabeu-Witteldeath, p=0.03 Yudeath, p=0.02 Lydeath, p=0.02 Ipdeath, p=0.43 Herasdeath, p=0.004 Kirengarecov. time, p=0.20 Sulaimandeath, p=0.01 Guisado-Vascodeath, p=0.19 Szente Fonsecahosp., p=0.0008 Cadegianideath, p=0.21 Simovahosp., p=0.01 Omranihosp., p=1.00 Agustiprogression, p=0.21 Suprogression, p=0.006 Amaravadino recov., p=0.13 Royrecov. time, p=0.96 Mokhtarideath, p<0.0001 Corradinideath, p=0.01 Milliondeath, p=0.0007 Sobngwino recov., p=0.44 Rodrigueshosp., p=1.00 Sawanpanyalertprogression, p=0.37 Atipornwanichprogression, p=1.00 Chechterhosp., p=0.004 HCQ early treatment studies FavorsHCQ Favorscontrol